<DOC>
	<DOCNO>NCT02739204</DOCNO>
	<brief_summary>The research development novel anti-tumor agent oral cancer slow , investigation reposition use currently available drug clinical , selective cyclooxygenase-2 ( COX-2 ) inhibitor ( Celebrex/Celecoxib ) maybe potential alternative strategy .</brief_summary>
	<brief_title>Concurrent Radiotherapy and/or Cisplatin With Without Celecoxib Patients With Primary Oral Squamous Cell Carcinoma</brief_title>
	<detailed_description>Celebrex ( Celecoxib ) form non-steroidal anti-inflammatory drug directly target COX-2 enzyme block inflammatory signal approve treat colon cancer . In preliminary finding , Celecoxib significantly inhibit cell growth , proliferation , migration , invasion epithelial-mesenchymal transition program oral squamous cell carcinoma cell ( OSCC ) line . The Institutional Review Board China Medical University Hospital ( CMUH ) approve combination treatment concurrent radiotherapy ( RT ) and/or Cisplatin without Celecoxib phase II clinical trial relapse-free primary OSCC patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . OSCC patient T1,2/ N0 without pathological risk feature 2 . OSCC patient T1,2/ N0,1 pathological risk feature 3 . OSCC patient T4a/ N2,3 1 . Pregnant woman paitents 2 . Taiwanese aboriginal patient 3 . Not primary OSCC patient 4 . OSCC patient dysfunction liver and/or kidney</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Celecoxib</keyword>
	<keyword>Relapse-free OSCC patient</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Survival</keyword>
	<keyword>Prognosis</keyword>
</DOC>